Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic

How I treat elderly patients with plasma cell dyscrasias

PDF) Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

OUH - Group members

Cardiovascular Toxicity of Proteasome Inhibitors: Underlying Mechanisms and Management Strategies: JACC: CardioOncology State-of-the-Art Review - ScienceDirect

OUH - Group members

Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data

PDF) Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the

Patient-versus investigator-reported peripheral neuropathy.

Health-related quality of life in the ENDEAVOR study: carfilzomib- dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma

Autologous stem cell transplantation for multiple myeloma patients with chronic kidney disease: a safe and effective option

Lene Kongsgaard Nielsen — Aarhus Universitet